NEW YORK — Enzo Biochem said last week that it intends to voluntarily delist its common stock from the New York Stock Exchange and transfer it to the OTCQX Best Market. It anticipates the delisting to become effective on or about April 17, with trading on the OTCQX to start on or about April 18. Enzo had received a delisting warning from the NYSE in January because it did not comply with the listing standards for market capitalization, stockholders' equity, and average closing stock price.
Eurofins said this week that it has finalized its acquisition of Synlab's clinical diagnostics operations in Spain. The companies said in October that they had reached a deal for an undisclosed amount for Eurofins to buy Synlab's clinical diagnostics testing services, including genetics and anatomical pathology services. The firms noted that Synlab had recorded revenues of €140 million ($151.4 million) in 2024. The combined company will have more than 2,000 employees and a network of labs with the capacity to process more than 100 million lab tests annually, the firms said.
German molecular diagnostics company Mainz Biomed reported this week that its 2024 revenues were relatively flat at $893,991 compared to $895,479 in 2023. The company trimmed its full-year net loss to $21.7 million, or $22.36 per share, from a net loss of $26.3 million, or $64.76 per share, in 2023. The company said that its lab network revenue increased 33 percent year over year, reflecting strong demand for its ColoAlert early detection test for colorectal cancer in Europe. Mainz finished 2024 with $6.2 million in cash. In November, Mainz said that it had signed an agreement with Thermo Fisher Scientific to codevelop a next-generation CRC screening test globally.
Paige said this week that it has received US Food and Drug Administration breakthrough device designation for its Paige PanCancer Detect pathology software that is used to aid the detection of cancer in tissue from multiple organs. The firm said that the artificial intelligence-developed digital pathology tool can be used to detect common cancers and rare variants in slide images from a broad range of tissues and organs.
Mexico's Longevity Medical Institute (LMI) is collaborating with Dutch social enterprise OncoInv to offer the OncoSeek multi-cancer early detection (MCED) test in Latin America by integrating the assay with LMI's in-house clinical laboratory cancer screening panel. OncoSeek was developed by San Diego-based liquid biopsy firm SeekIn and is designed to screen for nine common cancer types by detecting seven protein tumor markers. OncoInv and SeekIn previously struck an agreement designed to expand the global accessibility of SeekIn's tests, and OncoInv's new agreement with LMI will pair the OncoSeek test with LMI's panel, which analyzes more than 70 biomarkers, with the combined tests capable of detecting more than 12 types of cancer, the partners said in a statement this week.
In Brief This Week is a selection of news items that may be of interest to our readers but had not previously appeared on 360Dx.